FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890549955> ?p ?o ?g. }

• W2890549955 abstract "Prostate specific membrane antigen (PSMA), a type II membrane glycoprotein, is highly expressed in nearly all prostate cancers, with the highest expression in metastatic castration-resistant prostate cancer (mCRPC). The prevalence, increased surface expression in prostate tumors, and constitutive internalization make PSMA an attractive target for an antibody-drug conjugate (ADC) approach in anticancer treatment of patients with mCRPC. MEDI3726 (previously known as ADCT-401) is an ADC consisting of an engineered version of anti-PSMA antibody J591, site-specifically conjugated with DNA cross-linking pyrrolobenzodiazepine (PBD) dimer SG3249 for targeting prostatic cancer cells. Using prostate cancer cell line models, we have previously shown that MEDI3726 specifically binds to the extracellular domain of PSMA and, once internalized, releases the PBD dimer to cross link DNA and achieve potent in vitro and in vivo cytotoxicity. Here we investigated the in vivo activity of MEDI3726 in a series of LuCaP prostate cancer patient-derived xenograft (PDX) models. The selected LuCaP models had varying PSMA expression and heterogeneous genetic and phenotypic backgrounds. In agreement with the earlier cell line xenograft data, dose-dependent antitumor activity was observed in PSMA-positive PDX models with durable tumor regressions in models with high PSMA expression. In the PSMA-negative LuCaP 35CR PDX model, MEDI3726 did not have significant antitumor activity, thus highlighting target-mediated in vivo activity. Increased phosphorylation of histone H2AX was observed in xenografts dosed with MEDI3726, confirming DNA damage induced by interstrand cross-linking PBD dimer as the mechanism of antitumor activity of MEDI3726. In summary, MEDI3726 demonstrated potent and specific in vivo antitumor activity, concurrent with DNA damage, in clinically relevant prostate cancer PDX models. MEDI3726 is being evaluated in phase 1 clinical trial as an anticancer treatment in patients with metastatic castrate-resistant prostate cancer (NCT02991911). Citation Format: Song Cho, Francesca Zammarchi, Noel R. Monks, Kapil Vashisht, Ravinder Tammali, Kevin Schifferli, Patrick Strout, Wanda King, Karma Dacosta, Ryan Fleming, David G. Williams, Karin Havenith, Mary Jane Masson Hinrichs, Simon Chivers, Nazzareno Dimasi, Phil W. Howard, John A. Hartley, Steve Coats, Ronald Herbst, Patrick H. van Berkel, David A. Tice. MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A004." @default.
• W2890549955 created "2018-09-27" @default.
• W2890549955 creator A5006107477 @default.
• W2890549955 creator A5009094651 @default.
• W2890549955 creator A5012867126 @default.
• W2890549955 creator A5014214904 @default.
• W2890549955 creator A5017223848 @default.
• W2890549955 creator A5019757898 @default.
• W2890549955 creator A5029127660 @default.
• W2890549955 creator A5035773769 @default.
• W2890549955 creator A5039617409 @default.
• W2890549955 creator A5045583717 @default.
• W2890549955 creator A5050730829 @default.
• W2890549955 creator A5051207603 @default.
• W2890549955 creator A5055669649 @default.
• W2890549955 creator A5058484248 @default.
• W2890549955 creator A5068778166 @default.
• W2890549955 creator A5076501775 @default.
• W2890549955 creator A5078061615 @default.
• W2890549955 creator A5078346499 @default.
• W2890549955 creator A5079613331 @default.
• W2890549955 creator A5083508937 @default.
• W2890549955 creator A5085976480 @default.
• W2890549955 date "2018-08-14" @default.
• W2890549955 modified "2023-10-18" @default.
• W2890549955 title "Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models" @default.
• W2890549955 doi "https://doi.org/10.1158/1538-7445.prca2017-a004" @default.
• W2890549955 hasPublicationYear "2018" @default.
• W2890549955 type Work @default.
• W2890549955 sameAs 2890549955 @default.
• W2890549955 citedByCount "0" @default.
• W2890549955 crossrefType "proceedings-article" @default.
• W2890549955 hasAuthorship W2890549955A5006107477 @default.
• W2890549955 hasAuthorship W2890549955A5009094651 @default.
• W2890549955 hasAuthorship W2890549955A5012867126 @default.
• W2890549955 hasAuthorship W2890549955A5014214904 @default.
• W2890549955 hasAuthorship W2890549955A5017223848 @default.
• W2890549955 hasAuthorship W2890549955A5019757898 @default.
• W2890549955 hasAuthorship W2890549955A5029127660 @default.
• W2890549955 hasAuthorship W2890549955A5035773769 @default.
• W2890549955 hasAuthorship W2890549955A5039617409 @default.
• W2890549955 hasAuthorship W2890549955A5045583717 @default.
• W2890549955 hasAuthorship W2890549955A5050730829 @default.
• W2890549955 hasAuthorship W2890549955A5051207603 @default.
• W2890549955 hasAuthorship W2890549955A5055669649 @default.
• W2890549955 hasAuthorship W2890549955A5058484248 @default.
• W2890549955 hasAuthorship W2890549955A5068778166 @default.
• W2890549955 hasAuthorship W2890549955A5076501775 @default.
• W2890549955 hasAuthorship W2890549955A5078061615 @default.
• W2890549955 hasAuthorship W2890549955A5078346499 @default.
• W2890549955 hasAuthorship W2890549955A5079613331 @default.
• W2890549955 hasAuthorship W2890549955A5083508937 @default.
• W2890549955 hasAuthorship W2890549955A5085976480 @default.
• W2890549955 hasConcept C121608353 @default.
• W2890549955 hasConcept C126322002 @default.
• W2890549955 hasConcept C150903083 @default.
• W2890549955 hasConcept C159654299 @default.
• W2890549955 hasConcept C203014093 @default.
• W2890549955 hasConcept C20417620 @default.
• W2890549955 hasConcept C207001950 @default.
• W2890549955 hasConcept C2776235491 @default.
• W2890549955 hasConcept C2777325958 @default.
• W2890549955 hasConcept C2780192828 @default.
• W2890549955 hasConcept C502942594 @default.
• W2890549955 hasConcept C542903549 @default.
• W2890549955 hasConcept C71924100 @default.
• W2890549955 hasConcept C86803240 @default.
• W2890549955 hasConceptScore W2890549955C121608353 @default.
• W2890549955 hasConceptScore W2890549955C126322002 @default.
• W2890549955 hasConceptScore W2890549955C150903083 @default.
• W2890549955 hasConceptScore W2890549955C159654299 @default.
• W2890549955 hasConceptScore W2890549955C203014093 @default.
• W2890549955 hasConceptScore W2890549955C20417620 @default.
• W2890549955 hasConceptScore W2890549955C207001950 @default.
• W2890549955 hasConceptScore W2890549955C2776235491 @default.
• W2890549955 hasConceptScore W2890549955C2777325958 @default.
• W2890549955 hasConceptScore W2890549955C2780192828 @default.
• W2890549955 hasConceptScore W2890549955C502942594 @default.
• W2890549955 hasConceptScore W2890549955C542903549 @default.
• W2890549955 hasConceptScore W2890549955C71924100 @default.
• W2890549955 hasConceptScore W2890549955C86803240 @default.
• W2890549955 hasLocation W28905499551 @default.
• W2890549955 hasOpenAccess W2890549955 @default.
• W2890549955 hasPrimaryLocation W28905499551 @default.
• W2890549955 hasRelatedWork W1977334426 @default.
• W2890549955 hasRelatedWork W1994463565 @default.
• W2890549955 hasRelatedWork W2106003470 @default.
• W2890549955 hasRelatedWork W2810439727 @default.
• W2890549955 hasRelatedWork W2887583157 @default.
• W2890549955 hasRelatedWork W2896550082 @default.
• W2890549955 hasRelatedWork W3030930135 @default.
• W2890549955 hasRelatedWork W3211494956 @default.
• W2890549955 hasRelatedWork W4206748324 @default.
• W2890549955 hasRelatedWork W4240516920 @default.
• W2890549955 isParatext "false" @default.
• W2890549955 isRetracted "false" @default.
• W2890549955 magId "2890549955" @default.
• W2890549955 workType "article" @default.